Oncology-New York最新文献_第3页

Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy. 妇科癌症幸存者的生活经历：在意大利进行的一项调查

4区医学

Oncology-New York Pub Date : 2024-01-09 DOI: 10.46883/2024.25921012

Sonia La Spina, Paolo Scollo, Basilio Pecorino, Valentina Lombardo, Annamaria Motta, Rosa Gioia Calderone, Stefania Calì, Helga Lipari, Giuseppa Scandurra

{"title":"Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy.","authors":"Sonia La Spina, Paolo Scollo, Basilio Pecorino, Valentina Lombardo, Annamaria Motta, Rosa Gioia Calderone, Stefania Calì, Helga Lipari, Giuseppa Scandurra","doi":"10.46883/2024.25921012","DOIUrl":"10.46883/2024.25921012","url":null,"abstract":"Background: The study of health-related quality of life in survivors of gynecologic cancers is becoming increasingly important as 1.5 million survivors of gynecologic cancer in the United States and more are expected due to advances in diagnosis and treatment. This project investigated the perceived needs and lived experiences of survivors of gynecological cancer to help design supportive activities to be implemented in clinical practice.Methods: Patients were recruited in hospitals or through social media and responded to an online survey that was addressed to patients in Italy, specifically in Sicily, Puglia, and Campania. Patients with ovarian, endometrium, or cervix cancer were recruited among women attending Cannizzaro Hospital and Alleanza Contro il Tumore Ovarico (Alliance Against Ovarian Cancer) members.Results: Body image perception was changed in 82.3% of respondents, whereas familial relationships were described as changed by 27.5% of women. In 69.6% of patients, sexual habits were hindered by changes in the body, depression, pain, and awkwardness. Physicians informed patients about sexuality changes related to cancer extensively in 16.7% of cases and briefly in 19.6% of cases. The advice of a clinical sexologist was considered potentially helpful by 31.4% of patients and not potentially helpful by 47.1%, whereas 21.6% of patients had no opinion.Conclusions: Although sexual habits are often changed by cancer, women surviving gynecological cancer rarely seek medical advice in this area. Physicians should be trained to inform patients and to promote referrals to sexologists.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 1","pages":"15-19"},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139652147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Access to Electronic Health Records May Influence the Patient Experience. 尽早使用电子病历可能会影响患者体验。

4区医学

Oncology-New York Pub Date : 2023-12-14 DOI: 10.46883/2023.25921010

Mehmet Sitki Copur, Soe Min Tun, Adam J Horn

引用次数: 0

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer. 与晚期胰腺癌患者对全身疗法异常反应相关的基因组预测因子

4区医学

Oncology-New York Pub Date : 2023-12-14 DOI: 10.46883/2023.25921008

Suneel Kamath, Joanna Roopkumar, Ying Ni, Minqian Shen, Pablo Bejarano, Daniela Allende, Arun Nagarajan, Tim Nguyen, Bachar Dergham, Dale Shepard, Marc A Shapiro, Michael J McNamara, Bassam N Estfan, Kanika G Nair, Alok A Khorana

{"title":"Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer.","authors":"Suneel Kamath, Joanna Roopkumar, Ying Ni, Minqian Shen, Pablo Bejarano, Daniela Allende, Arun Nagarajan, Tim Nguyen, Bachar Dergham, Dale Shepard, Marc A Shapiro, Michael J McNamara, Bassam N Estfan, Kanika G Nair, Alok A Khorana","doi":"10.46883/2023.25921008","DOIUrl":"10.46883/2023.25921008","url":null,"abstract":"Introduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.Methods: We included exceptional responders and controls with advanced pancreatic cancer from Cleveland Clinic from April 2013 to August 2017. Exceptional responders were defined as patients with an overall survival of more than 18 months for metastatic disease and more than 24 months for locally advanced disease. Clinical data were obtained, and next-generation sequencing was performed. Statistical analyses comparing the 2 groups were performed using descriptive statistics, the Kaplan-Meier method, and the log-rank test.Results: The study comprised 4 exceptional responders and 6 controls. Both groups were well balanced in age, sex, race, and treatment regimens. Exceptional responders had significantly fewer nonsynonymous mutations than controls (2.25 vs 5.17; P = .014). A mutation count of less than 3 was associated with significantly better progression-free survival (17.2 vs 2.3 months; P = .002) and overall survival (29.4 vs 4.6 months; P = .013). Tumor mutational burden did not differ between exceptional responders and controls (4.88 vs 5.70 mut/Mb; P = .39).Conclusion: A lower number of nonsynonymous mutations may correlate with exceptional outcomes in patients with pancreatic cancer. These findings should encourage future studies into genomic signatures of exceptional response.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"37 12","pages":"488-495"},"PeriodicalIF":0.0,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review. 达那唑治疗骨髓增生异常综合征：系统综述。

4区医学

Oncology-New York Pub Date : 2023-12-14 DOI: 10.46883/2023.25921009

Sangam Shah, Rukesh Yadav, Abhinav Bhattarai, Sunraj Tharu, Prakash Sharma, Prativa Subedi, Arun Kharel, Pitambar Khanal, Pradeep Khanal Pradeep Khanal Mbbs Md, Sri Kollepara, Krishna Gundabolu

{"title":"Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review.","authors":"Sangam Shah, Rukesh Yadav, Abhinav Bhattarai, Sunraj Tharu, Prakash Sharma, Prativa Subedi, Arun Kharel, Pitambar Khanal, Pradeep Khanal Pradeep Khanal Mbbs Md, Sri Kollepara, Krishna Gundabolu","doi":"10.46883/2023.25921009","DOIUrl":"10.46883/2023.25921009","url":null,"abstract":"Purpose To study the potential utility of danazol for treating patients with myelodysplastic syndromes, with a focus on efficacy and adverse effects (AEs). Methods MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus were searched for relevant publications from inception June 1, 1950, until June 28, 2022. The studies were screened by title and abstract, followed by full-text screening. The quality of the included studies was assessed via a prespecified set of questionnaires. Data on the efficacy measures and adverse outcomes were extracted and included in a descriptive summary. Results Nine studies consisting of 246 participants were included in our review. The overall quality of the included studies was fair. The age of the participants ranged from 61 to 78 years. In all 9 studies, more male patients had been enrolled than female patients. Overall, a proportion of patients in all the studies reported a desired major response to a danazol dose of 400 to 800 mg/day. Few studies did not observe any improvement in the platelet count. Elevated liver enzyme levels, weight gain, headache, dermatitis, and weakness were the most common AEs observed. One study reported a fatal intracerebral hemorrhage in 1 participant. Conclusions Danazol has been effective in increasing platelet count and hemoglobin level. Despite a few AEs, danazol is a safe drug for the treatment of patients with myelodysplastic syndromes.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"37 12","pages":"480-487"},"PeriodicalIF":0.0,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the Changing Diagnostic Criteria of Gorlin-Goltz Syndrome: A Case Report. 探讨Gorlin-Goltz综合征诊断标准的变化:1例报告。

4区医学

Oncology-New York Pub Date : 2023-11-08 DOI: 10.46883/2023.25921007

Sahith Kumar Shetty, Vidya G Doddawad, Shyam Sundar, Shivananda S

引用次数: 0

Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman. 一位年轻女性透明细胞肉瘤的不寻常临床表现。

4区医学

Oncology-New York Pub Date : 2023-10-10 DOI: 10.46883/2023.25921005

Samia Asif, Brendan J Hurley, Sehr Haroon, Subodh Lele, Bhavina Sharma

{"title":"Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman.","authors":"Samia Asif, Brendan J Hurley, Sehr Haroon, Subodh Lele, Bhavina Sharma","doi":"10.46883/2023.25921005","DOIUrl":"10.46883/2023.25921005","url":null,"abstract":"Clear cell sarcoma (CCS) is a rare but aggressive malignancy that typically occurs in young adults and is characterized by soft tissue tumors of the extremities. CCS can be difficult to distinguish from metastatic melanoma based solely on histology and immunohistochemistry (IHC) because of the significant overlap between them. However, it is imperative to get an accurate clinical diagnosis, as it informs disease staging and treatment options for patient care. Present in approximately 75% of CCS cases, the EWSR1 gene rearrangement detected by fluorescence in situ hybridization (FISH) can help with establishing a diagnosis; the underlying reciprocal translocation has never been reported in cutaneous melanoma. We reviewed a case of a young woman who presented with a confusing picture of widespread lymphadenopathy, cutaneous metastases, and electrolyte derangements and was subsequently diagnosed with metastatic CCS.This case suggests possible value in performing molecular testing when a clinical picture does not correspond with what is expected for melanoma. It also raises the question of whether CCS cases may be underreported. This case highlights an uncommon presentation that may not be recognized as a manifestation of CCS by an oncologist who is not a sarcoma specialist. It is unclear how COVID-19 vaccination contributed to her clinical presentation, and it is also unclear whether an early diagnosis would have changed her clinical outcome.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"37 10","pages":"412-416"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma. 达拉单抗/透明质酸酶治疗多发性骨髓瘤期间继发性纯红细胞发育不全。

4区医学

Oncology-New York Pub Date : 2023-10-10 DOI: 10.46883/2023.25921006

Ludovic Saba, Kevin S Landau, Silvia Bunting, Chakra P Chaulagain

{"title":"Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma.","authors":"Ludovic Saba, Kevin S Landau, Silvia Bunting, Chakra P Chaulagain","doi":"10.46883/2023.25921006","DOIUrl":"10.46883/2023.25921006","url":null,"abstract":"Predominantly autoimmune in origin, severe normochromic, normocytic anemia with reticulocytopenia in the setting of the normal production of leukocytes and megakaryocytic lineages is known as pure red cell aplasia (PRCA), which is unlike aplastic anemia in which all lineages are affected due to a stem cell defect. PRCA can be primary (such as autoimmune) or acquired, which can be an acute self-limited illness or a chronic disease that may be induced by medications, including immunotherapy such as monoclonal antibodies (mAbs). Daratumumab is a mAb directed against CD38 used for the treatment of multiple myeloma and systemic amyloid light-chain amyloidosis. The intravenous formulation of daratumumab received initial FDA approval, and later approval was received for the subcutaneous formulation daratumumab and hyaluronidase-fihj. The subcutaneous version increases patient convenience and has become the preferred route of administration since its approval. We herein present the case of a patient with multiple myeloma who developed acquired DNMT3A-positive PRCA while transitioning to daratumumab/hyaluronidase after initial treatment with daratumumab.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"37 10","pages":"419-424"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50159214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spinal ATRT and Radiotherapy Case Report in an Adult Man. 一例成年男性脊髓ATRT和放射治疗病例报告。

4区医学

Oncology-New York Pub Date : 2023-09-13 DOI: 10.46883/2023.25921004

Fatma Betül Ayrak, Süheyla Aytaç Arslan, Yılmaz Tezcan

引用次数: 0

Active Surveillance of Prostate Cancer. 前列腺癌的主动监测。

4区医学

Oncology-New York Pub Date : 2017-01-15

Peter L Choyke, Stacy Loeb